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1. Introduction 
The skin being the largest organ in the body accounts for the most common cancer in 
humans. Skin cancer is typically of three types, basal cell carcinoma (BCC), squamous cell 
carcinoma (SCC) and melanoma. Despite accounting for only 4% of all cases, melanoma is 
the most deadly skin cancer, resulting in over 79% of skin cancer related deaths [1, 2]. In 
the year 2011 in the United States melanoma is thought to cause 70,230 cases (40,010 in 
men and 30,220 in women) with 8,790 deaths (5,750 in men and 3,040 in women) 
associated with the disease [3]. The median age at diagnosis is between 45 and 55, 
although 25% of cases occur in individuals before age 40. It is the second most common 
cancer in women between the ages of 20 and 35, and the leading cause of cancer death in 
women ages 25 to 30.  
There are multiple risk factors that contribute to the escalating incidences of melanomas in 
humans (Table 1). Among all, ultraviolet (UV)-radiation emitted from the sun is the main 
contributing factor towards the development of melanomas. It is well documented that UV-
radiation is absorbed by the chromophores such as DNA, RNA, protein and melanin in the 
skin [4]. This UV absorption in the skin results in different photochemical reactions and the 
secondary interactions involving ROS (reactive oxygen species) result in damaging effects. 
UV irradiation of the skin causes erythema, edema, hyperplasia, hyperpigmentation, 
sunburn cells, immunosuppression, photoaging and photocarcinogenesis [5, 6]. UV 
irradiation to skin also has direct effects on biomolecules such as formation of cyclobutane 
pyrimidine dimers (CPDs), 8-hydroxy-2'-deoxyguanosine (8-OHdG), protein oxidation and 
generation of ROS [4, 7, 8].  
Over the years, changes in lifestyle patterns have led to a significant increase in the amount 
of UV radiation that people receive, leading to a surge in the incidence of skin cancer and 
photoaging. Since these trends are likely to continue in the foreseeable future, the adverse 
effects of ultraviolet radiation have become a major human concern. One way of combating 
against the melanomas is through “chemoprevention” which is defined as the use of natural 
or synthetic agents to reverse, suppress or prevent premalignant lesions from progressing to 
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invasive cancers. Chemoprevention broadly is divided into 3 categories: (i) primary- 
preventing initial cancer in high risk individuals; (ii) secondary- preventing cancers in those 
with premalignant conditions; and (iii) tertiary- preventing second cancers in patients cured 
or an initial cancer [9, 10].  
 
 
Ultraviolet (UV) radiation 
 UVA 
 UVB 
Genetic syndromes 
 Xeroderma pigmentosum 
 Oculocutaneous albinism 
 Basal cell nevus syndrome 
Ionizing radiation 
 X-rays 
Other risk factors 
 Artificial UV radiation (tanning) 
 Skin color (having fair skin, especially with blue or hazel eyes) 
 History of lesions 
 Chronically injured or non-healing wounds 
 Working outdoors 
 Increasing age 
Table 1. Risk factors for melanomas [Reviewed in [136-142]] 
In recent years, natural agents have gained considerable attention because of their skin 
photoprotective effects [11, 12]. Nutritional agents with potential antioxidant, anti-
inflammatory, anti-mutagenic and anti-carcinogenic properties, and that have the ability to 
exert striking inhibitory effects on diverse cellular and molecular events are gaining 
considerable attention for the prevention of UV-induced skin damage [11-13]. Botanical anti-
oxidants have also been shown to reduce the incidence of ROS-mediated photocarcinogenic 
and photoaging. This has generated a great interest in using botanical supplements rich in 
anti-oxidants to delay photocarcinogenesis and prevent photoaging. This chapter presents 
an overview of selected few botanical agents and their protective properties of the skin 
against melanoma.  
2. Tea polyphenols 
Tea, derived from the plant Camellia sinensis, is the most popular beverage consumed by 
two-thirds of the world’s population. It is processed in different ways in different parts of 
the world to give green, black or oolong tea. “Black tea” is fully fermented, “oolong tea” is 
partially fermented and “green tea” is strained and not fermented. For the preparation of 
green tea, the young leaves are steamed to inactivate the enzymes thereby preserving as 
much as 90% of the polyphenols contained in fresh leaves from being degraded [14].  
The most studied formulation of tea is the green tea. Green tea contains characteristic 
polyphenolic conpounds, (-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate 
(ECG) and (-)-epicatechin (EC). A typical tea beverage (1 g leaf per 200 mL water in a 3 
minute brew) usually contains 250-300 mg tea solids comprised of 30-40% catechins and 3-
www.intechopen.com
 
Bioactive Food Components for Melanoma: An Overview 
 
193 
6% caffeine [14]. Green tea is considered a dietary source of anti-oxidants nutrients like 
polyphenols (catechin and gallic acid), carotenoids, tocopherols, ascorbic acid and certain 
phytochemical compounds. They may also function indirectly as anti-oxidants through 
inhibition of the redox-sensitive transcription factors, inhibition of pro-oxidant enzymes, 
such as inducible nitric oxide synthase, lipoxygenases, cyclooxygenases, and xanthine 
oxidase and induction of anti-oxidant enzymes, such as glutathione-S-transferases and 
superoxide dismutases [15]. 
The activity of tea polyphenols on the inhibition of skin tumorigenesis has been studied in 
depth. Studies have shown that green tea polyphenols (GTP) have a significant inhibitory 
effect on tumor induction in a chemically induced initiation-promotion mouse model [16]. 
EGCG significantly inhibited the binding of 3H-labelled polycyclic aromatic hydrocarbons to 
epidermal DNA. Topical application of EGCG resulted in significant inhibition in TPA-
mediated induction of epidermal ornithine decarboxylase (ODC) activity. The application of 
EGCG before challenge with DMBA also resulted in significant inhibition both in percentage 
of mice with tumors and the number of tumors per mouse compared with non-EGCG-
pretreated mice [17]. 
Oral consumption or topical application of brewed green tea or green tea extracts showed 
meaningful protection against ultraviolet or chemically induced carcinogenesis in mice. Oral 
consumption of brewed green tea at concentrations similar to human consumption (1.5-
2.5%) significantly inhibited UVB or TPA-induced tumorigenesis [18, 19]. Mechanistically, 
oral consumption of GTP resulted in decreased UVB-induced ODC and carboxylase (COX) 
activities [20]. Oral administration or intra-peritoneal injection of GTP achieved similar 
effects to inhibit the growth of UV-induced skin papillomas [18] or TPA-induced COX2 in 
rodent models [21]. EGCG treatment was found to result in a dose-dependent decrease in 
the viability and growth of A-375 amelanotic malignant melanoma and Hs-294T metastatic 
melanoma cell lines [22]. Oral administration of GTP was found to reduce UVB-induced 
tumor incidence, tumor multiplicity and growth in SKH-1 mice. Reduced expression of 
matrix metalloproteinase (MMP)-2 and MMP-9, vascular endothelial growth factor (VEGF) 
and proliferating cell nuclear antigen (PCNA) was also observed [23]. Furthermore, oral 
administration of green tea to UV-pretreated high risk mice for 23 weeks inhibited skin 
tumorigenesis [24]. Pretreatment of SKH-1 hairless mice with green tea for 2 weeks enhances 
UV-induced increase in epidermal p53, p21 (WAF1/CIP1) and apoptotic sunburns in the 
epidermis [25]. Furthermore, mice treated with green tea during chronic UVB irradiation 
changed the mutation profile of the p53 gene in early mutant p53 positive epidermal patches 
[26]. 
3. Curcumin 
Curcumin (diferuloylmethane) is a yellow substance extracted from the root of the turmeric 
plant Curcuma longa which belongs to the Zingiberaceae family. Curcumin has been used for 
centuries in indigenous medicine for the treatment of a variety of inflammatory and other 
diseases, and was shown for the first time in 1988, to have antimutagenic activity using the 
Ames Salmonella test [27]. It has a wide range of pharmacological activities including anti-
inflammatory, anti-cancer, anti-oxidant, wound healing and anti-microbial effects [28], as 
well as several documented clinical applications referenced to its anti-inflammatory and 
anti-oxidant properties. Curcumin is also a potent scavenger of a variety of reactive oxygen 
species (ROS) such as superoxide anion radicals, hydroxyl radicals, and nitrogen dioxide 
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radicals. The molecular basis of anti-carcinogenic and chemopreventive effects of curcumin 
is attributed to its effect on several targets including transcription factors, growth regulators, 
adhesion molecules, apoptotic genes, angiogenesis regulators and other cellular signaling 
molecules [29]. Curcumin is able to block multiple targets conferring protective effects 
against oxidative stress and inflammation and has proven useful in photoaging skin and 
photocarcinogenesis [30]. It was shown to induce apoptosis and cell cycle arrest in 
melanoma cells, associated with down-regulation of iNOS, the catalytic subunit of DNA-
dependent protein kinase, and up-regulation of p53, p21(CIP1), p27(KIP1) and Chk-2 [31] 
and its apoptosis inducible ability has also been associated to the Fas receptor/caspase-8 
pathway, independent of p53. It has been shown to down regulate the production of pro-
inflammatory cytokines such as tumor necrosis factor- (TNF-) and IL-1, and to inhibit 
the activation of transcription factors NF-B, and activator protein-1 (AP-1), which regulate 
the genes for pro-inflammatory mediators and protective anti-oxidant genes [32].  
Curcumin also suppresses the apoptotic inhibitor XIAP, decreases NF-B downstream 
target genes such as COX-2 and cyclin D1 expression and blocks it cell survival pathway 
and selectively induced apoptosis in melanoma cells but not in normal melanocytes [33, 34]. 
It was shown to inhibit proteasomal activity, inhibit Ca2+-adenosine triphosphatase (ATP) 
pump leading to accumulation of cytosolic calcium which then activates caspases, cleave 
p23 and downregulate the antiapoptotic Mcl-1 protein and thus inducing ER stress in 
melanoma cells [35]. The antiproliferative and proapoptotic effects induced by curcumin are 
shown to be independent of the B-Raf/ERK MAPK and the AKT pathway [36]. In spite the 
proapoptotic effects, curcumin has reportedly been associated with the inhibition of the 
ability of IFN-alpha, IFN-gamma, and IL-2 to phosphorylate STAT1 and STAT5 proteins 
[37], suggesting the possibility of it to adversely affect immune effector cells responses to 
clinically relevant cytokines with antitumor properties [36]. 
Moreover, curcumin was also reported to cause cell death in 8 melanoma cell lines, four 
with wild type and four with mutant p53. In highly metastatic murine melanoma cells 
B16F10 as well as other cells, it significantly inhibited the activity of MMP2 , collagenase and 
focal adhesion kinase (FAK), important components of the intracellular signaling pathway, 
meanwhile it enhanced the expression of anti-metastatic proteins such as tissue inhibitor 
metalloproteinase-2, nonmetastatic gene 23, and E-cadherin [38, 39]. Curcumin-treated 
B16F10 cells formed eight fold fewer lung metastasis in C57Black 6 mice [39], and showed a 
dose dependent reduction in their binding affinity to extracellular matrix (ECM) protein 
including fibronectin, vitronectin and collage IV and a reduced 5ǃ1 and 5ǃ3 integrin 
receptors expression in the cell adhesion assays. In stimulated melanoma cells, curcumin has 
been shown to suppress melanogenesis by down regulating melanogenesis related proteins 
such as MITF, tyrosinase and tyrosinase-related proteins 1 and 2 [40]. Interestingly, its 
antimetastatic effects has been linked to the modulation of the expression of integrin 
receptors, collagenase activity, tissue inhibitor metalloproteinase (TIMP)-2, nonmetastatic 
gene 23 (Nm23) and E-cadherin [38], [39].  
In resistant cases, a two hit combination of curcumin and other factors has been shown to 
enhance curcumin induced effects on melanoma cells in cell culture models. Small 
inhibitory RNA silencing of ABCA1 gene was shown to sensitize melanoma cells to the 
apoptotic effect of curcumin most likely due to a reduced basal levels of active NFB as well 
as a reduction of P65 expression [41]. Moreover, C6 ceramide was shown to sensitize 
melanoma cells to curcumin-induced cell death and apoptosis by partially increasing the 
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intrinsic apoptotic pathway [42]. More recently, it has been shown that a combination of 
curcumin and tamoxifen concomitantly induced apoptosis and autophagy in melanoma 
cells without affecting non-cancerous cells [43].  
Recent advances in view of selecting new antitumor agents with more potent and selective 
growth inhibitory activity has revolutionized the synthesis and testing of several analogous 
“curcumin-like” compounds. For instance the compound ,ǃ-unsaturated ketone D6 was 
shown to be more effective in inhibiting melanoma growth when compared to curcumin 
[44]. Synthetic curcuminoid derivatives have been analyzed  in vivo to test their inhibitory 
role to tumor-specific angiogenesis such that in mice injected with melanoma cells an 
intraperitoneal administration of tetrahydro curcumin, salicyl curcumin and curcumin III 
reduced the number of induced tumor-directed capillaries. Moreover, these curcuminoids 
have been shown to reduce serum Nitric Oxide (NO) and tumor-necrosis factor (TNF)- 
levels in treated animals, perhaps by decreasing the production by activated macrophages 
[45]. A small molecule FLLL32, an analog of curcumin and STAT3-specific inhibitor for 
melanoma therapy was shown to induce caspase-dependent apoptosis in cells through 
reduced STAT3 phosphorylation and retained the cellular response to cytokines with 
antitumor activity, and most remarkably did not reduce the function or viability of normal 
donor immune cells. FLLL32 has also been shown to inhibit IL-6-induced STAT3 
phosphorylation without reducing signaling due to IFN- and IL-2 [37, 46].  
Despite the highly recognized chemotherapeutic potential of curcumin, its poor solubility to 
water and fast degradation has significantly hindered its clinical application. However, 
amphiphilic block copolymer micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) 
used as solubilization and stabilization vehicles, were able to effectively solubilize 
curcumin, protect the degradation of encapsulated curcumin and control it release over 
several days [47]. A combination of curcumin and catechin was shown to inhibit the 
melanoma cell invasion by inhibiting MMPs, thus inhibiting lung metastasis [48]. Curcumin 
also was shown to inhibit the phosphorylation of Src kinase and STAT3 partly by 
downregulating PRL-3 and preventing melanoma cells from invading the draining lymph 
nodes [49]. In Mice, curcumin was reported to decrease the induction of epidermal ODC 
activity, epidermal cyclooxygenase and lipoxygenase enzyme levels, epidermal glutathione 
content, oxidation of DNA bases, and the number of tumors per mouse and tumor volume 
per mouse. Topical application of curcumin together with TPA was shown to induce 
epidermal hyperplasia and c-Jun and c-Fos expression in CD-1 mice [50]. Curcumin 
treatment successfully reduced the number and volume of tumors when given in diet to 
animals in which skin tumors had been inhibited with DMBA and promoted with TPA. The 
dietary consumption of curcumin resulted in decreased expression of proto-oncogenes, ras 
and fos, in the skin tissue [51, 52]. Topical application of curcumin together with TPA twice 
weekly for 18 weeks markedly inhibited TPA-induced tumor promotion [53]. Topical 
application on the dorsal side of the skin with curcumin before TPA exposure inhibited 
TPA-induced expression of c-fos, c-jun and c-myc [54]. Currently, several clinical trials are 
investigating the effect of curcumin in diverse cancerous and non-cancerous conditions but 
without any of them evaluating its effects against melanoma in human populations. 
4. Genistein  
Genistein (4', 5, 7-trihydroxyisoflavone) is a widely distributed isoflavone primarily present 
in soy, Ginkgo biloba extract, oregano and sage [55, 56]. It was first isolated from soybean in 
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1931 [57]. Increasing incidence has accumulated that genistein shows preventive and 
therapeutic use for cancers, osteoporosis and cardiovascular disease in both humans and 
animals. Genistein is a potent inhibitor of cytochrome P450-medicated activation of benz-a-
pyrene [58]. In an in vitro setting, genistein inhibits the activities of tyrosine protein kinase, 
topoisomerase II and ribosomal S6 kinase [59, 60]. Genistein has been reported to inhibit the 
growth of ras-transfected NIH3T3 cells without affecting the growth of normal cells [61]. 
Genistein can modulate the inflammatory responses that are commonly involved in the 
promotional stage of carcinogenesis [62]. It displays many anticancer properties which 
includes suppressing the growth of a variety of human gastrointestinal cancer cell lines, 
induction of differentiation of leukemia cells, and inhibition of endothelial cell angiogenesis 
relevant to tumor metastasis [63]. 
Genistein treatment in human NCTC 2544 keratinocytes prevented UV-induced 
enhancement of STAT1 (signal transducer and activator 1) thereby limiting lipid 
peroxidation [64]. Genistein inhibited UV-induced DNA damage as evaluated with the 
formation of pyrimidine dimers [65]. A dose-dependent inhibition of UVB-induced 
pyrimidine dimer formation was observed relative to increasing genistein concentrations 
[65]. Genistein substantially inhibits skin carcinogenesis and cutaneous aging induced by 
UV in mice and photodamage in humans [66]. Topical application of genistein before UVB 
radiation reduced the expression of c-fos and c-jun in the SENCAR mouse skin in a dose 
dependent manner [67]. Two promotion studies using DMBA and TPA protocol were 
conducted using CD-1 and SENCAR mice. Both these studies consistently showed that 
genistein substantially inhibited TPA-promoted skin tumorigenesis by reducing the tumor 
multiplicity. Genistein also inhibited DMBA-induced bulky DNA adduct formation and 
substantially suppressed TPA-stimulated H2O2 inflammatory responses and ODC activity in 
mouse skin [68].  
5. Fisetin 
Fisetin (3,7,3′,4′-tetrahydroxyflavone) is a flavonol, a structurally distinct chemical substance 
that belongs to the flavonoid group of polyphenols together with quercetin, myricetin and 
kaempferol with a chemical formula described earlier by the Austrian chemist Josef Herzig 
in 1891. It can be found in various plants, fruits and vegetables including apples, onions, 
persimmons and strawberries, where it functions as coloring agent [69], and was originally 
identified as an oxidative stress-induced nerve cell death inhibiting compound [70]. It has 
also been shown to possess neurotropic effects, promoting nerve cell differentiation and to 
enhance learning and memory in mice upon oral administration [71, 72]. In addition to its 
direct antioxidant and anti-inflammatory activities, fisetin can increase the intracellular 
levels of glutathione, and can as well reduce the production of lipid peroxides and their pro-
inflammatory by products [73]. In addition to its neuroprotective and anti-ageing effects, 
recent data suggests that fisetin possess anticancer properties, and have been shown to 
induce apoptosis in diverse cancer cell lines [73]. A more recent report showed that fisetin 
treatment of human melanoma cells resulted in decreased cell viability and disruption of 
Wnt/ǃ-catenin signaling associated with reduction of Wnt protein and its co-receptors 
expression, parallel by an increase expression of two endogenous Wnt inhibitor proteins, 
increased cytosolic levels of Axin and ǃ-TrCP and decreased phosphorylation of GSK3-ǃ 
[74]. An intraperitoneal administration of fisetin to mice was shown to significantly inhibit 
human melanoma tumor development and suggested that this "nontargeted therapies" is 
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promising to be effectively developed as a therapy armamater against melanoma since 
targeted therapies do not target all of the pathways required for melanoma growth [74].  
6. Resveratrol 
Resveratrol (3,5,4'-trihydroxystilbene), a polyphenolic flavonoid belonging to the stilbene 
family of phytoalexins, is found in grapes, nuts, berries and red wine. Resveratrol has been 
reported to exhibit a wide range of biological and pharmacological properties. Several 
plants including grapevine synthesize resveratrol when attacked by fungal pathogens [75]. 
Epidemiological studies indicate that the French have relatively lower risk of cardiovascular 
disease despite consuming a diet rich in fat. In reality, the high concentration of resveratrol 
in red wine consumed by the French is frequently cited to account for the “French Paradox” 
[5]. There have been extensive studies demonstrating that resveratrol possesses an ability to 
intervene in multistep carcinogenesis. In addition, resveratrol may be beneficial in the 
control of artherosclerosis, heart disease, arthritis or autoimmune disease. According to a 
study by Pezzerto et al. [76] resveratrol significantly reduced the number of tumors per 
mouse in a two-stage skin carcinogenesis model. In the  in vivo assay, resveratrol offered a 
60% reduction in DMBA and TPA-induced skin papillomas in mouse at 20 weeks [77]. 
Single topical application of resveratrol to SKH-1 hairless mice resulted in significant 
inhibition of UVB-mediated increase in skin edema. Resveratrol treatment to mouse skin 
also resulted in significant inhibition of UVB-mediated induction of COX and decreased 
ODC activity. It was also observed that resveratrol inhibited UVB-mediated increased level 
of lipid peroxidation which is a biomarker of oxidative stress [78]. Further, topical 
application of resveratrol to SKH-1 hairless mouse skin prior to UVB-radiation resulted in 
the inhibition of UVB-induced cellular proliferation, phosphorylation of surviving and 
upregulation of apoptotic factors (Smac and Diablo). The anti-proliferative effects of 
resveratrol might be mediated via modulation in the expression and function of cell cycle 
regulatory proteins like cyclin D1 and D2, cdk 2, 4, 6 and p21 and maybe associated with the 
inhibition of the MAPK pathway [79]. In normal human epidermal keratinocytes, 
resveratrol blocked UVB-mediated activation of NF-B in a dose- and time- dependent 
fashion. Resveratrol treatment in these cells also inhibited UVB-mediated phosphorylation 
and degradation of IƘBǂ and activation of IKKǂ [80]. Studies have demonstrated that 
topical application of resveratrol resulted in the inhibition of UVB-induced tumor incidence 
and a delay in the onset of skin tumorigenesis [81]. 
7. Pomegranate 
The pomegranate (Punica granatum) fruit has been used for centuries in ancient cultures for 
its medicinal purposes. Pomegranate is a rich source of two types of phenolic compounds: 
anthocyanins (delphinidn-3-glycoside, delphinidin-3,5-diglycoside, pelargonidin-3-
glycoside, pelargonidin-3,5-diglycoside, cyanidin-3-glycoside, cyanidin-3,5-diglycoside) and 
hydrolysable tannins. The other flavonoids present in pomegranate are quercetin, 
kaempherol and luteolin glycosides [82]. Pomegranate possesses strong anti-oxidant, anti-
inflammatory and anti-cancer properties [58, 83]. Pomegranate juice shows potent anti-
oxidant propterties that can be attributed to its high content of polyphenols (ellagic acid, 
EA), anthocyanins and other flavonoids [83]. 
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Studies have demonstrated that treatment of NHEK with pomegranate fruit extract (PFE) 
prior to UVB-exposure inhibited UVB-mediated phosphorylation of ERK1/2, JNK1/2 and 
p38 proteins in a dose- and time- dependent manner [84]. The treatment also resulted in 
inhibition of UVB-mediated degradation and phosphorylation of IBǂ, activation of IKK, 
nuclear translocation and phosphorylation of NF-B/p65 at Ser 536 [84]. Another study has 
reported that PFE treatment of NHEK inhibited UVA-mediated phosphorylation of STAT-3, 
AKT and ERK1/2 [85]. Topical application of PFE resulted in inhibition of TPA-induced 
tumor promotion in DMBA-initiated CD-1 mice. Mice pretreated with PFE showed reduced 
tumor incidence and lower tumor burden when compared to mice that did not receive PFE 
[86]. Treatment of HaCaT cells with PFE prior to UVB-exposure protected cells from UVB 
mediated decrease in cell viability, inhibited UVB-mediated decrease in endogenous 
glutathione levels, lipid peroxidation and expression of MMP-2 & MMP-9 [87].  
Delphinidin, a major anthocyanin present in pomegranate, protected NHEK from UVB-
mediated decrease in cell death [88]. The study reported an induction of apoptosis, a 
decrease in PCNA, activation of caspases and an increase in PARP expression [88]. Topical 
application of delphinidin to SKH-1 hairless mice inhibited UVB-mediated apoptosis and 
markers of DNA damage such as CPDs and 8-OHdG. Oral feeding of PFE to SKH-1 mice 
inhibited single UVB exposure mediated epidermal hyperplasia, infiltration of leucocytes, 
generation of hydrogen peroxide and lipid peroxidation [89]. PFE consumption further 
protects mouse skin against the adverse effects of UVB radiation by modulating UVB-
induced signaling pathways such as NF-B, MAPKs, c-Jun [86]. Topical and oral 
administration of pomegranate to humans was shown to augment the protective effects of 
sunscreens and afforded protection from UVB. A double blind, placebo-controlled clinical 
trial indicated that oral intake of PFE inhibited UV-induced pigmentation in the human skin 
[90]. 
8. Lupeol 
Lupeol, a triterpene found in fruits such as olives, mango, strawberry, grapes, figs and in 
medicinal plants like ginseng, shea butter plant, Tamarindus indica, Bombax ceiba [91] and has 
been used by native people in North America, Latin America, Japan, China, Africa and the 
Caribbean islands [92-97]. Lupeol has been demonstrated to inhibit various pharmacological 
activities under in vitro and  in vivo conditions. These include its beneficial activity against 
inflammation, cancer, arthritis, diabetes, heart disease, renal- and hepatic toxicity [94, 98-
107]. Topical application of lupeol alleviated TPA-induced inflammation in the ear mouse 
model [98] and decreased the expression of myeloperoxidase, a neutrophil specific marker, 
resulting in reduced infiltration into inflamed tissues [98]. Lupeol was found to reduce 
infiltration in mouse model of arthritis, an inflammation associated disease [108]. This 
beneficial effect was shown to be associated with the potential of lupeol to modulate the 
immune system. Lupeol was reported to suppress CD4+ and CD8+ T cell counts resulting in 
reduced cytokine expression (IL-2, IL-4,IFN-gamma) [109]. 
Epidemiological data suggests that the content of phytosterols (like lupeol) in the diet is 
associated with a reduction in common cancers including cancer of breast, prostate and 
colon [110, 111]. Tumorigenic animal models suggest that phytosterols modulate host 
systems potentially enabling more robust anti-tumor responses such as enhancing immune 
recognition of tumor cells, altering hormone-dependent growth of endocrine tumors, and 
modulating sterol biosynthesis [91, 111]. Mutation that occurs through DNA strand breaks 
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have been shown to form the precursor of cancer development [112-115]. An accumulation 
of these mutations transform neoplastic cells into malignant carcinomas. Lupeol was 
reported to exhibit strong anti-mutagenic activity under in vitro and  in vivo systems [102, 
116]. A study demonstrated that topical application of lupeol prevents DMBA-induced 
DNA strand breaks in murine skin [102]. Recently, lupeol was shown to inhibit benz-a-
pyrene induced genotoxicity in mouse models [117].  
There is increasing evidence that lupel inhibits tumor promotion in two stage skin 
carcinogenesis in mouse model [103]. Topical application of lupeol for 28 weeks was shown 
to significantly decrease tumor burden and tumor multiplicity [103]. The anti-tumor effects 
were observed to be associated with the potential of lupeol to modulate signaling pathways 
like NF-B and phosphatidylinositol-3-kinase (PI3K)/Akt, that play an important role in 
tumorigenesis [103]. Lupeol was shown to significantly inhibit NF-ƘB translocation to the 
nucleus and its DNA-binding activity in a mouse model of skin tumorigenesis [103]. Lupeol 
was also observed to inhibit ODC activity, an important biomarker of tumor promotion 
[103, 118]. Lupeol was also shown to inhibit growth of highly metastatic tumors of human 
melanoma origin by modulating the expression of BCl-2 and Bax proteins [104]. A recent 
study demonstrated that lupeol significantly inhibits the growth of metastatic melanoma 
cells that harbor constitutive activation of Wnt/ǃ-catenin signaling [119]. 
9. Silymarin 
Silymarin refers to three mixtures of flavonoids including silybin, silydianin and silychristin, 
a flavanolignan, isolated from the fruits and seeds of the plant milk thistle (Silybum 
marianum L. Gaertn.) which are protective against photocarcinogenesis. Mouse models 
studies elucidated that silymarin possess antioxidant, anti-inflammatory and 
immunomodulatory properties responsible for its efficacy against photocarcinogenesis [120, 
121]. Using UV-irradiated human melanoma cells silymarin was shown to protect against 
UV-induced apoptosis as well as modulation of the cell cycle with increase in the G2/M 
phase [120]. Silymarin’s potential to reduce UV-induced apoptosis is partially through 
activation of human deacetylase SIRT1 as well as by activation of the AKT and MAPK 
pathways [122]. An unclear knowledge of whether the protective effects of silymarin in 
melanoma cells is beneficial to melanoma prevention still lingers, but it was shown to 
enhanced the cytotoxic effect of anti-Fas agonistic antibody on human melanoma cells [123]. 
A more recent report showed that silybinin, a major active constituent of silymarin, 
prevented mitomycin C-induced apoptosis in human melanoma cells through suppression 
of the mitochondria-mediated intrinsic but not the extrinsic apoptosis pathway [124]. 
However, further studies are required to delineate the role of silymarin in the prevention of 
melanoma carcinogenesis. 
10. Other multifaceted food bioactive agents 
It has become clear that plants and phytosynthetic agents possess a broad spectrum of 
targeted and non-targeted potential drug compounds for cancer prevention and therapy. 
The anticancer properties of other fruits and vegetables are partly related to their isoprenoid 
constituents. A report showed that isoprenoids extracted from different plants possesses 
variable degrees of potency in suppressing the growth and proliferation of melanoma and 
other cancer cells [125]. Perillyl alcohol, derived from essential oils of lavendin, peppermint 
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and other diverse plants, is known to inhibit melanoma cell growth [125], but only few 
reports examined their efficacy in melanoma in situ. In a recent report topical perillyl 
alcohol was demonstrated to delay melanoma tumors appearance in TPras transgenic mice 
[126]. However, only a modest protective effect was detected in sun-burned skin subjects in 
a double-blind, randomized, phase II trial of topical perillyl alcohol possibly as a result of 
inadequate delivery through the epidermis [127]. 
Other bioactive agents such as garlic extract [128], exo-biopolymer from rice bran [129], and 
isothiocyanates extract of wasabi [130], as well as flavonoids such as hesperitin, naringenin 
[131] and chrysin derived from acacia honey [132] have been evaluated for their cytotoxic 
effect on melanoma cells. A limited number of studies have been effectuated on these 
compounds with several of them appearing as potential agents against melanoma, but the 
exact knowledge regarding their active excipient as well as their mechanistic potentials 
requires extensive in vitro cell culture and  in vivo animal model studies to elucidate. 
11. Nanotechnology for melanoma 
There are several issues in the effective prevention and therapy of melanoma which include 
development of novel agents, determination of optimal therapeutic combinations and 
effective delivery of agents to the tumor. The optimal agent delivery, which is the most 
important issue, is essential to improve drug concentrations, reduce side effects, and lower 
effective doses for better efficacy of the agents. We recently employed the use of 
nanotechnology to improve the outcome of chemopreventive intervention and coined the 
term ‘nanochemoprevention’ [119]. Utilization of nanotechnology for the development of 
efficient anticancer drug delivery system is one of the most recent advancement in medical 
science. The structure and tunable surface functionality of nanoparticulate system allows it 
to encapsulate/conjugate single or multiple entities either in the core or on the surface, 
rendering them ideal carriers for various anticancer drugs. Further, most drugs have poor 
solubility and low bioavailability, and are formulated with undesirable solvents, and, the 
use of nanocarriers, allows for the preparation of low water soluble cancer medications as 
solid or liquid formulations.  
For melanoma research, utilization of nanotechnology is a relatively new and rapidly 
developing field with constant research going on all around the world. So far no natural 
agents have been nanoformulated but constant work is going on and nanotechnology is 
being actively utilized in melanoma research. In one of the first study in the field, Banciu et 
al. [133] evaluated the inhibitory effects of glucocorticoids (GC) encapsulated in long-
circulating liposomes (LCL-PLP) (LCL-GC). The effects of all LCL-GC on the production of 
angiogenic/inflammatory factors  in vivo in the B16.F10 murine melanoma model as well as 
on the viability and proliferation of tumor cells and endothelial cells in vitro were 
investigated. The results showed that all four selected LCL-GC formulations inhibit tumor 
growth, albeit to different degrees. The differences in antitumor activity of LCL-GC correlate 
with their efficacy to suppress tumor angiogenesis and inflammation. The in vitro results 
presented suggested that LCL-BUP has strong cytotoxic effects on B16.F10 melanoma cells 
and the anti-proliferative effects of all LCL-GC towards angiogenic endothelial cells play a 
role in their antitumor activity.  
Tran et al. [134] discussed some promising new nanotechnology based therapies under 
development for the treatment of melanoma. This article summarized the utilization of 
liposomes for effective therapy of melanoma. A recent study demonstrated that the delivery 
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of doxorubicin using a nanotechnology-based platform significantly reduces the systemic 
toxicity of the drug, keeping unchanged its therapeutic efficacy in a mouse melanoma tumor 
model. Single-walled carbon nanotubes were used to conjugate a doxorubicin prodrug. The 
CNT-doxorubicin conjugate (CNT-Dox) induced time-dependent cell death in B16-F10 
melanoma cells in vitro. The nanoparticle was rapidly internalized into the lysosome of 
melanoma cells and was retained in the subcellular compartment for over 24 h. In an  in vivo 
melanoma model, treatment with the nanotube-doxorubicin conjugate abrogated tumor 
growth without the systemic side-effects associated with free doxorubicin. High-resolution 
photoacoustic tomography (PAT) with extraordinarily optical absorbing gold nanocages 
(AuNCs) was utilized in a study [135]. When bioconjugated with [Nle(4),D-Phe(7)]-alpha-
melanocyte-stimulating hormone, the AuNCs served as a novel contrast agent for  in vivo 
molecular PAT of melanomas with both exquisite sensitivity and high specificity. The 
bioconjugated AuNCs enhanced contrast approximately 300% more than the control, 
PEGylated AuNCs. A study optimized the antitumoral effects of direct electric current (DC) 
with poly(ɛ-caprolactone) (PCL) nanoparticles loaded with the amino acid tyrosine. The 
authors observed that the in vitro cytotoxicity of DC was significantly increased when 
associated with L-tyrosine-loaded NPs, using a murine multidrug-resistant melanoma cell 
line model. More studies involving nanotechnology are certainly required to be utilized in 
melanoma research that will open new avenues for prevention and therapy of melanoma. 
Studies involving nanoformulation of bioactive food components will be a welcome 
addition where nanotechnology could be involved to improve pharmacokinetics and reduce 
side effects associated with drugs. 
12. Conclusions 
With incessant efforts by the researchers worldwide, the prospect for the therapy of 
advanced melanoma has improved considerably and currently the future of this avenue is 
considered very optimistic. As described throughout this manuscript bioactive food 
components have great potential for melanoma therapy with each agent demonstrating 
multidimensional effects and targets as summarized under table 3. Although the preclinical 
data with these and other natural agents is encouraging, data from epidemiological studies 
is still needed to indicate a definite efficacy. Also, further understanding of the molecular 
and immunologic mechanisms that promote survival of melanoma tumor cells is needed. 
Several gene and protein modulation as depicted in table 2 could be targeted for better 
regulation of melanoma progression. Such information will undeniably lead to the 
development of better, more specific and less toxic agents. With careful planning and 
rational design of future human intervention trials and cohort studies natural agents could 
be easily exploited for betterment of patients with melanoma. 
Another approach that seems promising is utilizing a combination of two or more bioactive 
food components. In contrast to the single agent approach, researchers should direct their 
attention upon different natural and synthetic products as a complex mixture, a cocktail 
approach, which together may have synergistic anti-cancer benefits. This approach could be 
exploited both in vitro and  in vivo as well as in clinical and epidemiological studies. Since 
utilization of these bioactive food agents is relatively inexpensive, simple to use and 
possibly non-toxic, studies to assess its role in clinical melanoma is accessible and will be of 
interest. As many in vitro and  in vivo studies assessing the role of dietary agents on 
melanoma have shown significant effects against multiple targets, an in-depth analysis of 
our approach with the chemopreventive cocktail is warranted. 
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Gene Protein References 
Gene amplification
MITF  Mitf [142, 143] 
BRAF Braf [143, 144] 
c-MYC c-Myc [144-147] 
HRAS H-Ras [148, 149] 
CCND1 Cyclin D1 [150]
CDK4 Cdk4 [150]
CDH2 N-cadherin [145, 151] 
Gene losses 
ITGB3BP beta 3 endonexin [152]
CDKN2A P16Ink4a/ p14Arf [144, 150] 
PTEN Pten [145, 150] 
Table 2. Alterations involving known genes found in melanomas 
 
Agent Effects observed References 
Tea polyphenols 
Inhibition of skin tumorigenesis [16-19] 
Decreased UVB induced ODC, COX and 
tumorigenesis;  
[ 20, 21, 23-25 ] 
Curcumin 
Inhibition of photoaging and photocarcinogenesis; [30, 31] 
Modulation of multiple signaling pathways 
[29, 32-34, 39, 48, 50, 
54] 
Increase of intrinsic apoptotic pathway and/or 
autophagy 
[42, 43] 
Genistein 
Inhibition of UV-induced effects in vitro
Inhibition of inflammation and ODC activity
[64-66]
[68]
Fisetin 
Decreased cell viability and disruption of Wnt/-
catenin pathway
[74] 
Resveratrol 
Inhibition of skin tumorigenesis [76, 77, 81] 
Decreased oxidative stress [78] 
Pomegranate 
Modulation of multiple signaling pathways [84-87] 
Inhibit UV-mediated apoptosis and DNA damage, 
photoprotection 
[88, 89] 
Inhibit UV-induced pigmentation [90] 
Lupeol 
Inhibit DMBA-induced DNA strand breaks and 
B(a)P induced genotoxicity 
[102, 117] 
Inhibit tumor promotion, ODC activity etc. [103, 104, 118] 
Silymarin 
Exhibit antioxidant, anti-inflammatory and 
immunomodulatory properties
[120, 121] 
Table 3. Observed effects of various bioactive food components in skin cancer 
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13. Glossary 
UVB Ultraviolet B 
ROS reactive oxygen species 
CPD cyclobutane pyrimidine dimers 
8-OHdG 8-hydroxy-2'-deoxyguanosine 
EGCG epigallocatechin-3-gallate 
ECG epicatechin-3-gallate 
EC Epicatechin 
GTP green tea polyphenols 
TPA 12-O-tetradecanoyl-phorbol-13-acetate 
ODC ornithine decarboxylase  
DMBA 7,12-dimethylbenz-a-anthracene 
NF-ƘB Nuclear factor-kappa B 
TNF-ǂ tumor necrosis factor-alpha 
XIAP X-linked inhibitor of apoptosis 
MMP matrix metalloproteinase 
TIMP tissue inhibitor metalloproteinase  
MT1-MMP membrane type 1-matrix metalloproteinase 
FAK Focal Adhesion Kinase 
Nm23 Non-metastatic 23 
STAT1 signal transducer activator 1  
NHEK Normal Human Epidermal Keratinocyte 
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